METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION POWDER FOR SOLUTION

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

METHYLPREDNISOLONE (METHYLPREDNISOLONE SODIUM SUCCINATE)

Fáanlegur frá:

TEVA CANADA LIMITED

ATC númer:

H02AB04

INN (Alþjóðlegt nafn):

METHYLPREDNISOLONE

Skammtar:

125MG

Lyfjaform:

POWDER FOR SOLUTION

Samsetning:

METHYLPREDNISOLONE (METHYLPREDNISOLONE SODIUM SUCCINATE) 125MG

Stjórnsýsluleið:

INTRAMUSCULAR

Einingar í pakka:

2ML

Gerð lyfseðils:

Prescription

Lækningarsvæði:

ADRENALS

Vörulýsing:

Active ingredient group (AIG) number: 0106290004; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2014-04-02

Vara einkenni

_Methylprednisolone Sodium Succinate for Injection Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
METHYLPREDNISOLONE SODIUM SUCCINATE
FOR INJECTION
Methylprednisolone Sodium Succinate for Injection
Sterile Powder for Solution, 40mg, 125mg, 500 mg, 1 g Vials,
intravenous or intramuscular
USP
Glucocorticoid
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
MAY 06, 2014
Toronto, ON
M1B 2K9
Date of Revision:
Canada
September 23, 2022
www.tevacanada.com
Submission Control Number: 263266
_Methylprednisolone Sodium Succinate for Injection Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
WARNINGS AND PRECAUTIONS, SPECIAL POPULATIONS, PEDIATRICS
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................................
4
1 INDICATIONS
.........................................................................................................................
4
1.1 Pediatrics
........................................................................................................................
5
1.2 Geriatrics
........................................................................................................................
5
2
CONTRAINDICATIONS............................................................................................................
5
4 DOSAGE AND ADMINISTRATION
...........................................................................................
6
4.1 Dosing Considerations
.....................................................................................................
6
4.2 Recommended Dose and Dosage Adjustment
...............................